Centinel Spine reports record 47% increase in sales for first quarter 2011

A record 47% year-over-year sales increase for Q1, 2011 compared to the same period in 2010 was announced today by Centinel Spine, Inc. (Centinel™), innovator and a market leader in the Integrated Interbody Fusion™ spine medical device space.

“Centinel's record setting sales pace for the third straight quarter is a testament to surgeon acceptance of our lumbar and cervical implants as a de facto industry standard for Integrated Interbody Fusion devices.”

Centinel's Chairman and CEO, John J. Viscogliosi, said: "Centinel's record setting sales pace for the third straight quarter is a testament to surgeon acceptance of our lumbar and cervical implants as a de facto industry standard for Integrated Interbody Fusion devices.

"The STALIF TT™ remains a preferred product for use in anterior lumbar surgery and, when paired with STALIF C™ cervical device which offers domed and tapered device configurations, they give the STALIF™ line-up the unique ability to match a patient's anatomy. Together these products continue to drive growth. As I noted in announcing Q4, 2010 results, we continue to expect that the balance of 2011 will produce similar, stellar results," he added.

Centinel's President, Michael D. Will, said: "We've put a strong sales and distribution system in place whose quality and expertise are commensurate with that of the combined STALIF^® product line. With the expanded beta launch of our next generation lumbar device, STALIF MIDLINE™, due at the end of this month in Las Vegas at the SAS - The International Society for the Advancement of Spine Surgery - conference, we are confident of continuing, strong sales growth going forward. The equation is straightforward: great systems, plus long term clinical success, plus great people equal great results."